What Can We Learn from Herceptin® Trials in Metastatic Breast Cancer?

Publisher： Karger

E-ISSN： 1423-0232|63|1|39-46

ISSN： 0030-2414

Source： Oncology, Vol.63, Iss.1, 2002-11, pp. : 39-46

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What can we learn from ‘dropouts’ in clinical trials?

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 318-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 14-21

Karger

Access to resources Recommend Favorite

B‐type natriuretic peptide and heart failure: what can we learn from clinical trials?

By  

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 42, Iss. 9, 2015-09 ,pp. : 881-887

John Wiley & Sons Inc

Access to resources Recommend Favorite

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 37-42

Karger

Access to resources Recommend Favorite

New Combinations with Herceptin® in Metastatic Breast Cancer

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 50-57

Karger

Access to resources Recommend Favorite